Quinton Oswald is a Vero Beach, Florida, professional who led Notal Vision as CEO and currently advises the company, which develops leading-edge age-related macular degeneration (AMD)monitoring products. Vero Beach resident Quinton Oswald has an in-depth knowledge of trends in ophthalmology drug and device development.
In February 2023, Notal Vision, Inc., presented data on its home-based optical coherence tomography (OCT) system for treating wet AMD at the Angiogenesis, Exudation, and Degeneration and Macula Society 2023 meetings. A patient-centric approach, this platform extends the monitoring of retinal diseases beyond clinical settings to residential settings. The retinal OCT scans provide information that informs treatment moving forward.
The study involved several retina specialists and more than 200 subjects, with trials demonstrating the extended usability of the device by patients in a home setting. OCT images generated were analyzed at a reading center, with patient management guided by AI-based notifications, as well as a physician assessment of home OCT data.
As a physician with the Pepose Vision Institute described it, home OCT technologies both enable more individualized care and deliver insights into complex AMD dynamics. They fill the information void that exists in between medical office visits. Home OCT has received US Food and Drug Administration (FDA) “Breakthrough Device” designation, and the OCT machine learning algorithm has been shown in a previous study to be roughly the same as human experts when analyzing retinal fluid in patients with AMD.
